The cannabis medical cannabis company today announces the signing of an agreement with a pharmacy in the Sharon area to supply cannabis products, including dried inflorescences for medical use and other products, to the pharmacy, for a period of 3 years starting October 30, 2020. NIS.
The company is in advanced negotiations to sign a supply agreement for another pharmacy, under similar conditions to the current agreement, and with an expected revenue of NIS 4.5 million.
The company is updating today in a report to Maya on further developments in its activities, including the company conducting advanced negotiations with Teva Adir to enter into an agreement for the sale of all medical cannabis products in an area of 3.6 dunams at the Masuah breeding farm. As long as an agreement is signed, the total consideration for the company is expected to be about NIS 6 million.
In addition, the company is in advanced negotiations to enter into a strategic distribution agreement with a trading house with the aim of exclusively distributing Kanomed’s medical cannabis products, for a period of 3 years.
Further advanced negotiations The company is cooperating in the export of up to 1 ton of cannabis-based extracts and oils to Europe, with a local company, where each party will be entitled to 50% of the total revenue, as well as negotiations with the same company to enter into two production agreements under European standard And the Israeli.
Canomed continues to promote agreements in significant supply agreements with a number of entities in Israel, as well as in agreements for the purpose of exporting and supplying significant quantities to countries abroad.
It is owned by Kanomed, which is controlled by Manor and Kfir Gindi, INDOOR facility in Tziporit with a maximum production capacity of 10 tons and a growing farm in the Jordan Valley on an area of 15 dunams and a production capacity of 7.6 tons of inflorescences per year. Since the beginning of the year, the company has signed a number of agreements for cooperation in Israel amounting to tens of millions of shekels, as well as a strategic agreement with a distribution company in Germany, which is the company’s main target market in Europe.